Power Reimagined: an innovative,  guideline-recommended  regimen for your patients living  with  HIV


An innovative, guideline-recommended regimen for your
patients living with HIV


DOVATO is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

See a printable  post-prescription information booklet

Explore results  from clinical trials and real-world studies

View the ViiV Dovato data presented at international congress e.g. CROI, IAS, EACS


Dovato is now reimbursed throughout the UK in line with NHS commissioning criteria.3-5

Dovato prescription is recommended in line with SmPC requirements and exclusions, which should be evaluated by a healthcare professional

EACS Guidelines 2021

Recommended as an initial regimen for treatment-naïve patients and as a switch strategy for virologically suppressed patients who have been suppressed (HIV-1 <50 copies/mL) for the past 6 months and have no historical resistance or chronic HBV infection6

Requirements for treatment-naïve patients:

  • HBsAg negative
  • HIV viral load <500,000 copies/mL
  • No historical resistance

DHHS Guidelines 2019

Recommended as an initial regimen for most PLHIV (AI)* and as a good option for virologically suppressed patients who have no evidence of resistance to either drug7

Exclusions for treatment-naïve patients:

  • HIV viral load >500,000 copies/mL.
  • HBV co-infection.
  • Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available.

IAS Guidelines 2020

Recommended as an initial regimen for most people with HIV and as an appropriate switch strategy for virologically suppressed patients provided both agents are fully active. (AIa)8

Not recommended in:

  • Rapid start, because baseline laboratory evaluation results must be reviewed before initiation
  • Chronic hepatitis B
  • HIV-1 RNA >500,000 copies/mL, and perhaps a CD4+ T-cell count <200 cells/mm3, although the latter is unclear
  • Patients being treated for an active opportunistic infection
  • Guidelines recommend close monitoring for adherence and virological response is needed

*Rating of recommendations: A=strong; B=moderate; C=optional. Rating of evidence: I=data from randomised controlled trials; II=data from well-designed non-randomised trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomised switch studies; III=expert opinion.7


AIa=Strong panel support with evidence from ≥1 RCTs published in the peer-reviewed literature.8


  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  2. van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study). Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Slides O441.
  3. NHS England Clinical Commissioning Policy https://www.england.nhs.uk/publication/dolutegravir-lamivudine-for-the-treatment-of-human-immunodeficiency-virus-hiv-1-infected-adults-and-adolescents-over-12-years-of-age/ Accessed February 24, 2021.
  4. https://www.scottishmedicines.org.uk/media/4708/dolutegravir-plus-lamivudine-dovato-abbreviated-final-august-2019-for-website.pdf Accessed February 24, 2021.
  5. All Wales Medicines Strategy Group Advice on Dovato http://www.awmsg.org/awmsgonline/app/appraisalinfo/3659 Accessed February 24, 2021
  6. European AIDS Clinical Society. Guidelines. Version 10.1 https://www.eacsociety.org/files/guidelines-10.1.finalsept2020.pdf Accessed February 24, 2021
  7. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed February 24, 2021. Updated December 18, 2019. 
  8. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults 2020 Recommendations of the International Antiviral Society–USA Panel. JAMA 2020. doi:10.1001/jama.2020.17025

PM-GB-DLL-WCNT-210009 I November 2021